A Multi-center, Randomized, Double-blind, Parallel, Placebo-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of FURESTEM-AD Inj. for Moderate to Severe Chronic Atopic Dermatitis
Phase of Trial: Phase III
Latest Information Update: 13 Sep 2019
Price : $35 *
At a glance
- Drugs Umbilical cord mesenchymal stem cell therapy-Kangstem Biotech (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors Kangstem Biotech
- 10 Sep 2019 Status changed from recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 12 Feb 2018 Planned number of patients changed from 206 to 194.